Evidence map›Paper›PMID 26752297›Full record

ArticlePloS one2016

A Novel Molecular Strategy for Surveillance of Multidrug Resistant Tuberculosis in High Burden Settings.

Halima M Said, Nicole Kushner, Shaheed V Omar, Andries W Dreyer, Hendrik Koornhof, Linda Erasmus, Yasmin Gardee, Ivy Rukasha, Elena Shashkina, Natalie Beylis and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Cryptic Microheteroresistance Explains Mycobacterium tuberculosis Phenotypic Resistance.American journal of respiratory and critical care medicine · 2017
    Article
  5. Article
  6. Correlation ofFrontiers in microbiology · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Halima M SaidCentre for Tuberculosis, National Institute of Communicable Diseases, Sandringham, South Africa.
Nicole KushnerPublic Health Research Institute, Rutgers University, Newark, New Jersey, United States of America.
Shaheed V OmarCentre for Tuberculosis, National Institute of Communicable Diseases, Sandringham, South Africa.
Andries W DreyerCentre for Tuberculosis, National Institute of Communicable Diseases, Sandringham, South Africa.
Hendrik KoornhofCentre for Tuberculosis, National Institute of Communicable Diseases, Sandringham, South Africa.
Linda ErasmusCentre for Tuberculosis, National Institute of Communicable Diseases, Sandringham, South Africa.
Yasmin GardeeCentre for Tuberculosis, National Institute of Communicable Diseases, Sandringham, South Africa.
Ivy RukashaCentre for Tuberculosis, National Institute of Communicable Diseases, Sandringham, South Africa.
Elena ShashkinaPublic Health Research Institute, Rutgers University, Newark, New Jersey, United States of America.
Natalie BeylisNational Health Laboratory Service, Groote Schuur Hospital, Cape Town, South Africa.
Gilla KaplanThe Bill & Melinda Gates Foundation, Seattle, Washington, United States of America.
Dorothy FallowsPublic Health Research Institute, Rutgers University, Newark, New Jersey, United States of America.
Nazir A IsmailCentre for Tuberculosis, National Institute of Communicable Diseases, Sandringham, South Africa.
Rutgers, The State University of New Jersey · USBill & Melinda Gates Foundation · USGroote Schuur Hospital · ZAUniversity of Pretoria · ZA

Funding

Emerging XDR-TB: Host and Pathogen ContributionsR01AI080737 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI FALLOWS, DOROTHY A. · 2009 to 2013
$2.9M
NIAID NIH HHS R01 AI080737
6 · The paper itself

Abstract

backgroundIn South Africa and other high prevalence countries, transmission is a significant contributor to rising rates of multidrug resistant tuberculosis (MDR-TB). Thus, there is a need to develop an early detection system for transmission clusters suitable for high burden settings. We have evaluated the discriminatory power and clustering concordance of a novel and simple genotyping approach, combining spoligotyping with pncA sequencing (SpoNC), against two well-established methods: IS6110-RFLP and 24-loci MIRU-VNTR.

methodsA total of 216 MDR-TB isolates collected from January to June 2010 from the NHLS Central TB referral laboratory in Braamfontein, Johannesburg, representing a diversity of strains from South Africa, were included. The isolates were submitted for genotyping, pncA sequencing and analysis to the Centre for Tuberculosis in South Africa and the Public Health Research Institute Tuberculosis Center at Rutgers University in the United States. Clustering rates, Hunter-Gaston Discriminatory Indexes (HGI) and Wallace coefficients were compared between the methods.

resultsOverall clustering rates were high by both IS6110-RFLP (52.8%) and MIRU-VNTR (45.8%), indicative of on-going transmission. Both 24-loci MIRU-VNTR and IS6110-RFLP had similar HGI (0.972 and 0.973, respectively), with close numbers of unique profiles (87 vs. 70), clustered isolates (129 vs. 146), and cluster sizes (2 to 26 vs. 2 to 25 isolates). Spoligotyping alone was the least discriminatory (80.1% clustering, HGI 0.903), with 28 unique types. However, the discriminatory power of spoligotyping was improved when combined with pncA sequencing using the SpoNC approach (61.8% clustering, HGI 0.958). A high proportion of MDR-TB isolates had mutations in pncA (68%, n = 145), and pncA mutations were significantly associated with clustering (p = 0.007 and p = 0.0013 by 24-loci MIRU-VNTR and IS6110-RFLP, respectively), suggesting high rates of resistance to pyrazinamide among all MDR-TB cases and particularly among clustered cases.

conclusionWe conclude that SpoNC provides good discrimination for MDR-TB surveillance and early identification of outbreaks in South Africa, with 24-loci MIRU-VNTR applied for pncA wild-type strains as needed.

Indexed as

Cost of IllnessPopulation SurveillanceCluster AnalysisGenotyping TechniquesHumansMutationMycobacterium tuberculosisTuberculosis, Multidrug-Resistant

Identifiers

PMID26752297
PMCPMC4713439
OpenAlexW2238863216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.